IN THE MATTER OF the Patent Act R.S.C. 1985, c. P-4, as amended AND IN THE MATTER OF Horizon Pharma (the "Respondent") and the medicine Cysteamine Bitartrate sold by the Respondent under the trade name “Procysbi”
Notice of Hearing
TAKE NOTICE that the Patented Medicine Prices Review Board (the “Board”) will hold a hearing in its offices in the Standard Life Centre, 333 Laurier Avenue West, 18th Floor, Ottawa, Ontario, on a date to be determined by the Hearing Panel no later than February 27, 2019.
The purpose of the hearing is to determine whether, under sections 83 and 85 of the Patent Act, the Respondent is selling or has sold the medicine Cysteamine Bitartrate sold by the Respondent under the trade name “Procysbi” in any market in Canada at a price that, in the Board’s opinion, is or was excessive and if so, what order, if any, should be made.
Procysbi is indicated for the treatment of the rare and life-long multisystem genetic disorder nephropathic cystinosis. Among other symptoms, nephropathic cystinosis impairs the filtering function of the kidney, eventually progressing to kidney failure and necessitating a kidney transplant.
Persons wishing to intervene in the proceeding are required to apply to the Board for leave to intervene. Such persons should contact the Secretary of the Board for further information on the procedure.
All requests for information should be addressed to the Secretary of the Board: Guillaume Couillard, Standard Life Centre, Suite 1400, 333 Laurier Avenue West, Ottawa, Ontario K1P 1C1; 1 877 861-2350 (Toll-free number); (613) 288-9635 (Direct line); Guillaume.Couillard@pmprb-cepmb.gc.ca (E-mail).